Intercept Pharmaceuticals logo
Intercept Pharmaceuticals ICPT
report update icon

Quarterly report 2023-Q3
added 05-16-2026

Intercept Pharmaceuticals Financial Statements 2022-2002 | ICPT

Annual Financial Statements Intercept Pharmaceuticals

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2002

Market Cap

706 M 520 M 814 M 3.92 B 2.87 B 1.46 B 2.68 B 3.54 B 3.24 B 1.23 B 215 M - - - - - -

Shares

33.8 M 31.9 M 33 M 31.7 M 28.5 M 25.1 M 24.7 M 23.7 M 20.8 M 18 M 6.28 M 3.33 M 3.33 M - - - -

Historical Prices

20.9 16.3 24.7 124 101 58.4 109 149 156 68.3 34.2 - - - - - -

Net Income

-20.8 M -36.3 M -275 M -345 M -309 M -360 M -413 M -226 M -283 M -67.8 M -43.6 M -12.7 M -15.1 M -14.4 M -13.7 M -18.7 M -

Revenue

77.2 M 68.6 M 234 M 252 M 180 M 37.7 M 13.8 M 2.78 M 1.74 M 1.62 M 2.45 M 1.81 M - - - - -

Cost of Revenue

984 K 1.2 M 2.35 M 4.21 M 2.52 M 1.37 M - - - - - - - - - - -

Gross Profit

- - - 248 M 177 M 130 M 25 M 2.78 M - - - 1.81 M - - - - -

Operating Income

-18.9 M -29.2 M -230 M -312 M -285 M -336 M -403 M -229 M -113 M - - - - - - - -

Interest Expense

21.4 M 54.4 M 48.1 M 41.1 M 30.5 M 29.3 M 14.2 M 2.73 M 776 K - - - - - - - -

EBITDA

-18.3 M -26.4 M -227 M -309 M -281 M -331 M -399 M -227 M -113 M 106 K 201 K 411 K 480 K - - - -

Operating Expenses

- - - 560 M 465 M 467 M 427 M 232 M 115 M 41.1 M 21.4 M 15.6 M - - - - -

General and Administrative Expenses

176 M 177 M 261 M 317 M 255 M 274 M 274 M 104 M 34.6 M 13.1 M 5.18 M 4.21 M 3.64 M - - - -

All numbers in USD currency

Quarterly Income Statement Intercept Pharmaceuticals

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

41.8 M 41.7 M 41.7 M 41.5 M 34.3 M 29.7 M 29.7 M 29.6 M 31.7 M 33.2 M 33.1 M 33 M 33 M 33 M 32.6 M 32.9 M 32.7 M 31.3 M 29.8 M 29.7 M 29.6 M 29.2 M 25.3 M 25.2 M 25.1 M 25 M 24.9 M 24.8 M 24.7 M 24.6 M 24.5 M 24.4 M 24.2 M 24 M 22.2 M 21.4 M 21.3 M 21 M 19.5 M 19.3 M 19.2 M 17 M 16.6 M 15.2 M 3.33 M 3.33 M 3.33 M 3.33 M 3.33 M 3.33 M 3.33 M

Net Income

-2.79 M -5.86 M -32.1 M - 267 M -7.53 M -17.3 M - -3.63 M -11.1 M -40.4 M -52.1 M -66.5 M -63.3 M -93 M -98.2 M -84.8 M -71.4 M -90.3 M -88 M -64.5 M -75.2 M -81.6 M -111 M -72.6 M -86.6 M -89.9 M -120 M -88.8 M -77.3 M -127 M -88.3 M -50.9 M -47.9 M -39.4 M -34.8 M -35.8 M 33.5 M -258 M -12.4 M -31.7 M -13.5 M -10.2 M -30.7 M -5.19 M -5.09 M -2.68 M -3.65 M -2.84 M -2.92 M -3.33 M

Revenue

88.8 M 83.7 M 68 M - 77.6 M 71.8 M 88.6 M - 92.8 M 96.6 M 81.7 M 83.3 M 79.5 M 77.2 M 72.7 M 71.5 M 62 M 66.3 M 52.3 M 53.3 M 47 M 43.6 M 36 M 37.7 M 41.3 M 30.9 M 21 M 13.8 M 5.18 M 5.52 M 445 K 445 K 445 K 445 K 1.45 M - - - - - - - - - - - - - - - -

Cost of Revenue

197 K 185 K 222 K - 424 K 309 K 758 K - 658 K 618 K 810 K - 1.83 M 1.88 M 852 K - 487 K 677 K 574 K - 519 K 713 K 280 K - 172 K 279 K 97 K - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-4.62 M -7.12 M -31.6 M - -10.1 M -13.4 M -10.3 M - -6.22 M 760 K -29.3 M -40.6 M -55.2 M -52 M -83.4 M -89.3 M -75.5 M -63.7 M -83.9 M -82 M -58.3 M -69.8 M -75.5 M -105 M -66.2 M -80.5 M -84 M -114 M -83 M -78.1 M -127 M -88.9 M -51.8 M -48.8 M -39.7 M - - - - - - - - - - - - - - - -

Interest Expense

1.8 M 2.81 M 2.81 M - 5.24 M 6.67 M 6.67 M - 14.1 M 12.6 M 12.4 M - 12.1 M 11.9 M 11.8 M - 11.8 M 9.88 M 7.84 M - 7.67 M 7.59 M 7.51 M - 7.35 M 7.28 M 7.21 M - 7.06 M 796 K 726 K - 889 K - - - - - - - -20.6 M -5.86 M -3.39 M - -3.41 K 117 K 680 K - 2.89 K - -

EBITDA

-4.34 M -6.94 M -31.5 M - -9.65 M -13 M -9.9 M - -3.66 M 2.51 M -28.5 M -40.6 M -52.9 M -50.5 M -82.7 M -89.3 M -72.7 M -59 M -81.5 M -82 M -54.7 M -67.3 M -74.2 M -105 M -62.9 M -78.6 M -83.2 M -114 M -80.8 M -76.6 M -127 M -88.9 M -50.7 M -48.2 M -39.4 M - 210 K 130 K 61.7 K - 79.4 K 30 K 23 K - 24 K 80 K 74 K - 160 K - -

Operating Expenses

- - - - - - - - - - - - - - - - - - 136 M - 105 M 113 M 111 M - 108 M 111 M 105 M - 88.2 M 83.6 M 128 M - 52.2 M - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

45.4 M 53.3 M 57.7 M - 43.3 M 40 M 50 M - 53.3 M 57.7 M 59.3 M - 70.6 M 93.4 M 98.6 M - 76.8 M 69.7 M 77.2 M - 56.8 M 65.2 M 62.5 M - 61.4 M 66.9 M 61.1 M - 44.4 M 42.3 M 90.4 M - 24.7 M 21 M 13.1 M - 9.14 M 7.95 M 5.65 M 4.73 M 3.12 M 2.89 M 2.4 M 2.18 M 991 K 944 K 1.06 M 1.04 M 1.15 M 894 K 1.13 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Intercept Pharmaceuticals ICPT
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Intercept Pharmaceuticals plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.31 6.5 % $ 166 M schweizSchweiz
ADMA Biologics ADMA Biologics
ADMA
$ 9.7 3.21 % $ 2.31 B usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 27.89 0.3 % $ 4.23 B usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 13.3 1.06 % $ 364 M israelIsrael
AbbVie AbbVie
ABBV
$ 265.08 0.02 % $ 469 B usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 193.45 0.24 % $ 9.62 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.28 2.24 % $ 28.1 M usaUSA
Adagene Adagene
ADAG
$ 2.97 0.62 % $ 175 M chinaChina
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.53 2.65 % $ 293 M usaUSA
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 4.04 0.24 % $ 2.7 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 62.21 0.06 % $ 11.9 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.85 0.2 % $ 929 M canadaCanada
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.16 0.45 % $ 3.56 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 7.83 0.87 % $ 341 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 14.19 1.17 % $ 1.27 B usaUSA
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.08 0.3 % $ 255 M usaUSA
Codexis Codexis
CDXS
$ 1.38 0.72 % $ 120 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.6 4.3 % $ 496 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.26 1.48 % $ 148 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.12 0.28 % $ 2.07 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.04 4.94 % $ 49.3 M israelIsrael
AbCellera Biologics AbCellera Biologics
ABCL
$ 12.31 0.12 % $ 3.68 B canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 5.26 2.69 % $ 645 M usaUSA
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.19 1.26 % $ 13.4 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 22.45 1.05 % $ 711 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 112.94 3.29 % $ 11.7 B usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 7.74 0.19 % $ 103 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.31 0.74 % $ 87.6 M usaUSA
Curis Curis
CRIS
$ 0.95 0.98 % $ 12.5 M usaUSA
CorMedix CorMedix
CRMD
$ 7.69 0.06 % $ 554 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 55.76 1.2 % $ 5.01 B schweizSchweiz
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 12.54 8.21 % $ 990 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 31.71 2.62 % $ 3 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 1.68 0.59 % $ 13.5 M usaUSA
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 65.81 0.04 % $ 7.9 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 450.61 1.61 % $ 35.2 B usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 7.56 7.16 % $ 355 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 20.46 5.52 % $ 3.53 B usaUSA
Precision BioSciences Precision BioSciences
DTIL
$ 6.36 10.62 % $ 81.6 M usaUSA
Dyadic International Dyadic International
DYAI
$ 0.41 3.72 % $ 14.8 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.69 0.17 % $ 239 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 3.97 1.46 % $ 22.5 M usaUSA